Drug Profile
Research programme: purine receptor agonists - BioLineRx
Alternative Names: BL-6010; EDP 01; EDP 22Latest Information Update: 07 May 2012
Price :
$50
*
At a glance
- Originator Bar-Ilan Research & Development Company
- Developer BioLineRx
- Class Purines; Small molecules
- Mechanism of Action Purinergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma; Type 2 diabetes mellitus
Most Recent Events
- 22 Mar 2012 Discontinued - Preclinical for Glaucoma in Israel (unspecified route)
- 22 Mar 2012 Discontinued - Preclinical for Type-2 diabetes mellitus in Israel (PO)
- 10 Sep 2010 Preclinical trials in Type-2 diabetes mellitus in Israel (PO)